CN118063336B - Fatty acid diethylamine acyl alcohol ester citrate - Google Patents
Fatty acid diethylamine acyl alcohol ester citrateInfo
- Publication number
- CN118063336B CN118063336B CN202410113487.8A CN202410113487A CN118063336B CN 118063336 B CN118063336 B CN 118063336B CN 202410113487 A CN202410113487 A CN 202410113487A CN 118063336 B CN118063336 B CN 118063336B
- Authority
- CN
- China
- Prior art keywords
- citrate
- fatty acid
- caking
- raw material
- potassium pyrophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/02—Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P21/00—Plant growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/50—Use of additives, e.g. for stabilisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Health & Medical Sciences (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the technical field of plant regulators, and particularly relates to fatty acid diethylaminoethanol ester citrate. The fatty acid diethylaminoethanol ester citrate provided by the invention consists of a fatty acid diethylaminoethanol ester citrate raw material and 4-5% of an anti-caking agent, wherein the anti-caking agent consists of silicon dioxide powder and potassium pyrophosphate. Through the compounding of the silicon dioxide powder and the potassium pyrophosphate, the silicon dioxide powder wraps and blocks capillary holes on the surface of the raw material when the potassium pyrophosphate fixes the moisture on the surface of the raw material of the fatty acid diethyl amino ethanol ester citrate, so that the moisture migration inside raw material particles is prevented, the anti-caking performance of the raw material of the fatty acid diethyl amino ethanol ester citrate in a high-temperature and high-humidity environment is synergistically improved, and the raw material has higher anti-caking rate under the humidity condition of 50 ℃ or below and not higher than 90%.
Description
Technical Field
The invention belongs to the technical field of plant regulators, and particularly relates to fatty acid diethylaminoethanol ester citrate.
Background
The fatty acid diethylaminoethanol ester citrate (DA-X citrate) is widely applied to various soils and crops as a plant regulator, can improve the content of chlorophyll, protein and nucleic acid in plants and photosynthesis, improve the activities of peroxidase and nitrate reductase, promote the carbon and nitrogen metabolism of plants, enhance the absorption of water and fertilizer and the accumulation of dry matters of plants, regulate the water balance in bodies, enhance the disease resistance, drought resistance and drought resistance of crops and fruits and vegetables, delay the acid aging of plants, promote the premature of crops, increase the yield and improve the quality of crops.
The DA-X citrate raw medicine is in powder form under normal temperature, but the DA-X citrate raw medicine is easy to absorb moisture and easy to dehydrate and recrystallize under high temperature, so that the DA-X citrate raw medicine is bonded together to cause caking of the raw medicine, and a plurality of inconveniences exist in the production, storage, transportation and use processes of the DA-X citrate raw medicine.
Disclosure of Invention
The invention aims to provide fatty acid diethylaminoethanol ester citrate, which solves the problems of inconvenient production, storage, transportation and use caused by easy caking of raw materials of the fatty acid diethylaminoethanol ester citrate in a high-temperature and high-humidity environment.
In order to solve the technical problems, the technical scheme of the fatty acid diethylaminoethanol ester citrate is as follows:
A fatty acid diethylaminoethanol ester citrate consists of a fatty acid diethylaminoethanol ester citrate raw material and 4-5% of an anti-caking agent, wherein the anti-caking agent consists of silicon dioxide powder and potassium pyrophosphate.
According to the invention, the prior art is improved, the anti-caking agent is added into the raw material of the fatty acid diethylaminoethanol ester citrate, and the silicon dioxide powder and the potassium pyrophosphate are compounded, so that the silicon dioxide powder is wrapped to block capillary holes on the surface of the raw material when the potassium pyrophosphate fixes the moisture on the surface of the raw material, thereby preventing the moisture migration in raw material particles, synergistically improving the anti-caking performance of the raw material of the fatty acid diethylaminoethanol ester citrate in a high-temperature and high-humidity environment, and enabling the raw material to have higher anti-caking rate under the humidity condition of 50 ℃ or below and not higher than 90%.
In order to further improve the anti-caking capacity of the fatty acid diethylaminoethanol ester citrate in a high-temperature and high-humidity environment, the mass ratio of the silicon dioxide powder to the potassium pyrophosphate is preferably 3 (1-3).
In order to further improve the anti-caking property of the fatty acid diethylaminoethanol ester citrate in a high-humidity environment, preferably, the mass ratio of the silicon dioxide powder to the potassium pyrophosphate is 3 (1-2).
In order to further improve the anti-caking performance of the fatty acid diethylaminoethanol ester citrate, the caking rate is lower than 35 percent, and the anti-caking agent is preferably composed of a fatty acid diethylaminoethanol ester citrate raw material and 5 percent of anti-caking agent, wherein the mass ratio of the silicon dioxide powder to the potassium pyrophosphate is 3:2.
In order to further improve the anti-caking property of the fatty acid diethylaminoethanol ester citrate under high temperature conditions, preferably, the fatty acid diethylaminoethanol ester citrate raw medicine comprises a diethylaminoethanol caproate citrate raw medicine, a diethylaminoethanol caprylate citrate raw medicine and a diethylaminoethanol caprate citrate raw medicine. The alkyl group of the fatty acid diethylaminoethanol ester citrate is sensitive to temperature change, and the temperature change influences the state of the raw medicine and further influences the caking property of the raw medicine.
In order to further prevent the migration of moisture inside the raw material particles, preferably, the silica powder is prepared by a vapor deposition method.
In order to further improve the clogging efficiency of the capillary holes on the surface of the raw material, the particle size of the silica powder is preferably 12nm to 19 μm.
In order to further reduce the caking rate by increasing the clogging efficiency of the capillary holes on the surface of the raw material, the caking rate is made to be less than 45%, and the particle diameter of the silica powder is preferably 12 to 15nm.
Drawings
FIG. 1 is a bar graph of the caking rate of DA-X citrate prodrugs at different temperatures;
FIG. 2 is a graph showing the morphological changes of DA-X citrate prodrugs at different temperatures;
FIG. 3 is a bar graph of the moisture content of DA-X citrate prodrug at different temperatures;
FIG. 4 is a bar graph of the caking rate of DA-X citrate prodrugs at different humidities;
FIG. 5 is a graph showing the morphological changes of DA-X citrate prodrugs at different humidities;
FIG. 6 is a bar graph of the moisture content of DA-X citrate prodrugs at different humidities;
FIG. 7 is a bar graph of caking rates of DA-X citrate prodrugs incorporating a single anticaking agent at different temperatures;
FIG. 8 is a graph showing the morphology change of a DA-X citrate prodrug incorporating a single anticaking agent at different temperatures;
FIG. 9 is a bar graph of the moisture content of DA-X citrate prodrugs incorporating a single anticaking agent at different temperatures;
FIG. 10 is a bar graph of caking rates of DA-X citrate prodrugs incorporating a single anticaking agent under high humidity conditions;
FIG. 11 is a graph showing the morphological changes of DA-X citrate prodrugs incorporating a single anticaking agent under high humidity conditions;
FIG. 12 is a bar graph of the moisture content of DA-X citrate prodrugs incorporating a single anticaking agent under high humidity conditions.
Detailed Description
The technical conception of the fatty acid diethylaminoethanol ester citrate provided by the invention is as follows:
a fatty acid diethylaminoethanol ester citrate comprises a fatty acid diethylaminoethanol ester citrate raw material and 4-5% of an anti-caking agent, wherein the anti-caking agent comprises silicon dioxide powder and potassium pyrophosphate. The fatty acid diethyl amino ethanol citrate (DA-X citrate) raw material is sensitive to temperature due to alkyl fatty alcohol chains, so that the raw material can generate state transition in the temperature change process, caking of the raw material is easy to occur, and due to water solubility of the raw material, the raw material absorbs water in a high-humidity environment to cause dissolution of the surfaces of raw material particles, so that the raw material particles close to each other form a 'crystal bridge' in gaps to cause caking of the raw material.
In specific embodiments, the primary drug of fatty acid diethylaminoethanol ester citrate (DA-X citrate) comprises primary drug of diethylaminoethanol caproate citrate (DA-6 citrate), primary drug of diethylaminoethanol caprylate citrate (DA-8 citrate) and primary drug of diethylaminoethanol caprate citrate (DA-10 citrate), and the chemical formula of the primary drug of DA-6 citrate is C 18H33NO9, and the chemical structure is shown as formula I:
The chemical formula of the DA-8 citrate original drug is C 20H37NO9, and the chemical structure is shown as formula II:
the chemical formula of the DA-10 citrate original drug is C 22H41NO9, and the chemical structure is shown as formula III:
DA-6, DA-8 and DA-10 citrate raw drugs have similar biological activities and are all in powder form at normal temperature.
In a specific embodiment, the silica powder is produced by Yingchuang industries, inc22LS, kayin chemical Co., ltd820A, saidThe particle size of the powder of 22LS is 12-19 mu m, and the powder is prepared fromThe particle size of the 820A powder is 12-15 nm, and the 820A powder is prepared by a vapor deposition method.
In a specific embodiment, the preparation method of the fatty acid diethylaminoethanol ester citrate comprises the following steps of adding silicon dioxide powder and potassium pyrophosphate with corresponding mass into a raw material of the fatty acid diethylaminoethanol ester citrate, and uniformly mixing to obtain the fatty acid diethylaminoethanol ester citrate.
Embodiments of the present invention will be further described with reference to the following specific examples. The chemical reagents referred to in the following examples are commercially available conventional products unless otherwise specified. The raw materials of DA-6, DA-8 and DA-10 are purchased from Zhengzhou Zheng chemical industry products, the content is 98%, the particle size is larger than 60 meshes, the potassium pyrophosphate is purchased from Shifang Shibelieved chemical industry, the anti-caking agent 1 is purchased from Zibo navigation, the active ingredient is anhydrous magnesium sulfate, the anti-caking agent 2 is purchased from Tianjin Dragon, the nano alumina and NT-104 are purchased from Guangzhou benefit polymer material, and the Petro AG is purchased from Ackersu.
1. Specific examples of fatty acid diethylaminoethanol ester citrates of the invention
The formula composition of the fatty acid diethylaminoethanol ester citrate is shown in table 1.
Table 1 formulation composition of fatty acid diethylaminoethanol ester citrate
The fatty acid diethylaminoethanol ester citrate of example 1, comprised 96% of DA-6 citrate prodrug and 4% of an anti-caking agent, which was 3%22LS, 1% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 2, comprised 95% of DA-6 citrate prodrug and 5% of an anti-caking agent, which was 3% 22LS, 2% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 3, comprised 96% of DA-6 citrate prodrug and 4% of an anti-caking agent, which was 2% 22LS, 2% of potassium pyrophosphate;
the fatty acid diethylaminoethanol ester citrate of example 4, comprised 96% of DA-6 citrate prodrug and 4% of an anti-caking agent, which was 3% 820A, 1% potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 5, comprised 95% of DA-6 citrate prodrug and 5% of an anti-caking agent, which was 3% 820A, 2% potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 6, comprised 96% of DA-6 citrate prodrug and 4% of an anti-caking agent, which was 2% 820A, 2% potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 7, comprised 96% of DA-8 citrate prodrug and 4% of an anti-caking agent, which was 3% 22LS, 1% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 8, comprised 95% of DA-8 citrate prodrug and 5% of an anti-caking agent, which was 3% 22LS, 2% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 9, comprised 96% of DA-8 citrate prodrug and 4% of an anti-caking agent, which was 2% 22LS, 2% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 10, comprised 96% of DA-8 citrate prodrug and 4% of an anti-caking agent, which was 3% 820A, 1% potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 11, comprised 95% of DA-8 citrate prodrug and 5% of an anti-caking agent, which was 3% 820A, 2% potassium pyrophosphate;
the fatty acid diethylaminoethanol ester citrate of example 12, comprised 96% of DA-8 citrate prodrug and 4% of an anti-caking agent, which was 2% 820A, 2% potassium pyrophosphate;
the fatty acid diethylaminoethanol ester citrate of example 13, comprised 96% of DA-10 citrate prodrug and 4% of an anti-caking agent, which was 3% 22LS, 1% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 14, comprised 95% of DA-10 citrate prodrug and 5% of an anti-caking agent, which was 3% 22LS, 2% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 15, comprised 96% of DA-10 citrate prodrug and 4% of an anti-caking agent, which was 2% 22LS, 2% of potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 16, comprised 96% of DA-10 citrate prodrug and 4% of an anti-caking agent, which was 3% 820A, 1% potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 17, comprised 95% of DA-10 citrate prodrug and 5% of an anti-caking agent, which was 3% 820A, 2% potassium pyrophosphate;
The fatty acid diethylaminoethanol ester citrate of example 18, comprised 96% of DA-10 citrate prodrug and 4% of an anti-caking agent, which was 2% 820A, 2% potassium pyrophosphate.
2. Experimental example
In the following experimental examples, the samples were tested for caking properties at different temperatures and at different humidities according to the following methods:
1. caking Performance test at different temperatures
(1) Taking fatty acid diethylaminoethanol ester citrate composed of different formulas as a test sample, wherein each test sample comprises 4 parts and 20 g of each part;
(2) Putting 4 test samples into 50ml square transparent PE bottles respectively, and sealing the bottle mouth by a sealing machine to prevent gas from entering;
(3) Placing the sealed PE bottle into constant temperature ovens with different temperatures, wherein the temperatures of the constant temperature ovens are 25 ℃, 35 ℃,45 ℃ and 50 ℃ respectively, closing an oven door for sealing, and keeping the internal temperature of the oven;
(4) After 2 days of standing in a constant temperature oven, the test sample in the oven was taken out.
2. Caking Performance test at different humidity
(1) Taking fatty acid diethylaminoethanol ester citrate composed of different formulas as a test sample, wherein each test sample comprises 1 part and 20 g;
(2) Respectively placing the test samples into 50ml square transparent PE bottles, and opening the bottle mouth;
(3) Placing PE bottles into humidity control boxes with different humidities, setting the temperature of the humidity control boxes to be 25 ℃ and the humidity to be 90%, closing the humidity control box doors, and keeping the temperature and the humidity inside the control boxes;
(4) After 2 days of placement in the humidity control cabinet, the test sample in the cabinet was removed.
3. Sample caking rate calculation method
Cutting the PE bottle placed for 2 days at different temperatures from the upper part without cutting samples, pouring out the test samples in the PE bottle placed for 2 days at different temperatures and different humidities, sieving with a 20-mesh sieve, judging that the powder with the particle size of more than 20 meshes is qualified, judging that the sample with the particle size of less than 20 meshes is agglomerated, and calculating the caking rate according to the formula 1:
4. DA-X citrate original drug water content test
The method comprises the steps of measuring the original weight M 0 of a DA-X citrate original medicine sample to be measured to be 4 g+/-0.1 g, drying at a constant temperature of 105 ℃ and weighing to be M x, wherein the ratio of the weight loss before and after constant temperature drying to the original weight is the water content.
This experimental example illustrates the results of the formulation screening of examples 1-18.
1. Anti-caking property test of fatty acid diethylaminoethanol ester citrate raw material
(1) Caking Performance test at different temperatures
The DA-6, DA-8 and DA-10 citrate raw medicines are placed at 25 ℃, 35 ℃, 45 ℃ and 50 ℃ for a period of time to test the high Wen Jiekuai rate, the test result is shown in figure 1, the morphology change of the raw medicines is shown in figure 2, the water content of the raw medicines is tested after the raw medicines are placed at different temperatures for a period of time, and the test result is shown in figure 3.
As can be seen from fig. 1-2, the DA-X citrate prodrugs did not agglomerate when stored for 3 days at 25 ℃, but the DA-X citrate prodrugs increased significantly with time at 35-45 ℃ with increasing temperature, wherein the DA-8 and DA-10 citrate prodrugs reached 100% caking at 2 days, and all three DA-X citrate prodrugs agglomerated within 1 day with further increasing temperature, when the temperature reached above 50 ℃. This illustrates that temperature is an important factor affecting the caking of the DA-X citrate master, the higher the temperature, the more severe the caking phenomenon.
As can be seen from fig. 3, the water content of the three DA-X citrate prodrugs does not change much with increasing temperature and prolonged holding time, indicating that the temperature has no influence on the caking property of the DA-X citrate prodrugs and is not influenced by the component content of the crude drugs. The water content of the DA-6 citrate raw medicine is about 0.35%, the water content of the DA-8 citrate raw medicine is about 0.44%, the water content of the DA-10 citrate raw medicine is about 0.46%, and the water content difference of the three DA-X citrate raw medicines is caused by the initial water content difference of the DA-X citrate raw medicine.
(2) Caking Performance test at different humidity
The DA-6, DA-8 and DA-10 citrate raw medicines are placed for a period of time under the conditions of 25 ℃ and the environmental humidity of 50%, 60%, 70%, 80%, 85% and 90%, the high wet caking rate is tested, the test result is shown in figure 4, the morphology change of the raw medicines is shown in figure 5, the water content of the raw medicines is tested after being placed for a period of time under different humidity, and the test result is shown in figure 6.
From fig. 4-5, it can be seen that the environmental humidity has a greater influence on the caking property of the DA-X citrate active ingredient, and at an environmental humidity of 50-85%, the greater the environmental humidity, the higher the caking rate of the DA-X citrate active ingredient, i.e., the greater the environmental humidity the active ingredient is subjected to, the easier the caking. The caking rate of the DA-6 citrate original drug is slightly smaller than that of DA-8 and DA-10 citrate under the same humidity condition. As can be seen from fig. 5, the DA-X citrate raw material having a low caking rate is in the form of powder, and as the ambient humidity increases, the free powder of the partially agglomerated DA-X citrate raw material becomes smaller, and when the caking rate reaches 90% or more, the DA-X citrate raw material is in the form of an overall bulk, with little or no free powder.
As can be seen from fig. 6, as the humidity of the environment increases, the water content of the DA-X citrate raw material increases accordingly, which indicates that the DA-X citrate raw material has hygroscopicity, and the greater the ambient humidity, the greater the internal humidity of the corresponding DA-X citrate raw material, and in addition, the three DA-X citrate raw materials have less difference in hygroscopicity compared with each other.
2. Anti-caking property test of fatty acid diethylaminoethanol ester citrate raw drug introduced into single anti-caking agent
(1) Caking Performance test at different temperatures
Adding 5% of anti-caking agent 1, 1% of potassium pyrophosphate, 1% of nano alumina, 1% of NT-104, 1% of AG, 5% of anti-caking agent 2, 1%, 2% and 3% of anti-caking agent into DA-6, DA-8 and DA-10 citrate raw materials respectively22LS, 1%, 2%, 3%820A, and testing the caking rate of the DA-X citrate introduced with the single anti-caking agent at different temperatures, wherein the testing results are shown in tables 2-4, the drawing of a bar graph is shown in figure 7, 5% of the anti-caking agent in figure 7 is 5% of the anti-caking agent 1,5% of the anti-caking agent is the anti-caking agent 2, and the change of the original medicine form at different temperatures is shown in figure 8.
TABLE 2 caking Rate of DA-6 citrate with Single anticaking agent introduced at different temperatures
TABLE 3 caking Rate of DA-8 citrate with Single anticaking agent introduced at different temperatures
TABLE 4 caking Rate of DA-10 citrate with Single anticaking agent introduced at different temperatures
As can be seen from tables 2-4 and FIGS. 7-8, the incorporation of a single anti-caking agent reduced the caking rate of the DA-X citrate stock from 100% to 0% differently, as compared to the absence of the anti-caking agent, with an anti-caking effect of 3%820 A=2%820 A=1%820A = 5% anticaking agent 2>3%22LS >2%22LS >1%22LS >1% NT-104>1% AG >1% nano aluminum chloride >5% anticaking agent 1 (anhydrous magnesium sulfate) >1% potassium pyrophosphate > no anticaking agent was added. The anhydrous magnesium sulfate and potassium pyrophosphate have the anti-caking effect by fixing the surface moisture of the DA-X citrate raw material, and the nano aluminum oxide, the NT-104 and the AG anti-caking agent,22LS and820A is used for blocking capillary holes on the surface of the raw medicine by wrapping so as to play a role in preventing caking.
Wherein 5% of the anti-caking agent 2, 1-3% of the amount820A ensures that the caking rate of the DA-X citrate raw material at different temperatures is 0%, and can effectively avoid the caking phenomenon of the DA-X citrate raw material at high temperature.
The analysis of the cause of the caking of the DA-X citrate original drug is probably due to the fact that citrate is chelated on a DA-X long chain, the chelating capacity is strong in a low-temperature state, the chelating capacity is reduced along with the increase of the temperature, the stability is reduced, and the caking phenomenon occurs.
The water content test results of the DA-X citrate with the single anti-caking agent introduced at different temperatures for a period of time are shown in fig. 9, and it can be seen from fig. 9 that the water content of the DA-X citrate with the single anti-caking agent introduced at different temperatures for a period of time does not change greatly, and the water content difference of the three DA-X citrate raw materials is determined by the water content of the initial raw materials and is not affected by the introduced anti-caking agent.
(2) Caking Performance test under high humidity conditions
The caking rate of the DA-X citrate original drug introduced with the single anti-caking agent at 25 ℃ and the ambient temperature is 90%, the test result is shown in figure 10, the 5% anti-caking agent in figure 10 is 5% anti-caking agent 1, the 5% anti-caking agent is anti-caking agent 2, and the morphological change of the original drug is shown in figure 11. From FIGS. 10-11, it can be seen that the difference in caking effect under the condition of 90% of ambient humidity is large after different anticaking agents are introduced into DA-X citrate original drug, and that anticaking agent 1, potassium pyrophosphate, nano-alumina, NT-104, AG, 1%22LS、2%22LS have substantially no anti-caking effect, but 3%22LS,2%820A,3%820A can play a better role in preventing caking, and the caking rate of the DA-X citrate raw material can be reduced to 40% at most.
The water content test result of the DA-X citrate original drug with the single anti-caking agent introduced under the condition that the ambient temperature is 90% is shown in table 5, a water content bar chart is drawn and shown in fig. 12, the 5% anti-caking agent in fig. 12 is 5% anti-caking agent 1, and the 5% anti-caking agent is anti-caking agent 2.
TABLE 5 moisture content of DA-X citrate at 90% ambient humidity
As can be seen from table 5 and fig. 12, the moisture content of the DA-X citrate stock after the addition of the anti-caking agent at 90% humidity was not very different, indicating that the moisture absorption properties of the stock were not increased or decreased by the addition of the anti-caking agent at 90% ambient humidity. DA-6 citrate original drug is addedThe humidity was slightly reduced after 22LS, possibly with the addition of an anti-caking agent which would reduce the hygroscopic properties of the material.
2. Anti-caking performance test of fatty acid diethylaminoethanol ester citrate raw material after introduction of compound anti-caking agent
According to the caking property test of the single anti-caking agent, 3 percent of the anti-caking agent is screened out22LS and 1%, 3%820A was formulated with other antiblocking agents, and the formulation composition of the formulation is shown in Table 6.
TABLE 6 formulation composition of DA-X citrate prodrugs and formulated anti-caking agents
(1) Caking Performance test at different temperatures
The results of the caking rates at different temperatures for the 39 formulations described above are shown in tables 7-9.
TABLE 7 caking Rate of DA-6 citrate with incorporated anti-caking agent at different temperatures
TABLE 8 caking Rate of DA-8 citrate with incorporated anti-caking agent at different temperatures
TABLE 9 caking Rate of DA-10 citrate with incorporated anti-caking agent at different temperatures
As can be seen from tables 7-9, except for the 28# formulation (4% addition22 LS), the addition of the anti-caking agent in other formulas can improve the anti-caking performance of the DA-X citrate raw medicine at high temperature, and compared with the addition of a single anti-caking agent, the anti-caking agent can better prevent the DA-X citrate raw medicine from caking after being compounded with other anti-caking agents, and the caking rate is 0% under the condition of 25-50 ℃ and no caking phenomenon occurs.
(2) Caking Performance test under high humidity conditions
The caking rates of the above 39 formulations at 25℃ambient humidity of 90% are shown in Table 10.
As can be seen from Table 10, under the condition of 90% of ambient humidity, the caking rates of the 3# to 7# and 9# to 13# formulas in the DA-6 citrate raw medicine are respectively lower than that of the 2# and 8# formulas, the caking rates of the 16 # to 20# and 22# to 26# formulas in the DA-8 citrate raw medicine are respectively lower than that of the 15# and 21# formulas, and the caking rates of the 29# to 33# and 35# to 39# formulas in the DA-10 citrate raw medicine are respectively lower than that of the 28# and 34# formulas, so that the compound anti-caking agent can better prevent the DA-X citrate raw medicine from caking compared with the single anti-caking agent. In the compound formula, the agglomeration rate of the SIPERNAT series and the potassium pyrophosphate compound is higher than that of the SIPERNAT series and the nano alumina or the NT-104 compound.
In addition, DA-X citrate is added into the original medicine820A (8 # to 13 #), compared with the addition of22LS (No. 2-No. 7) has lower caking rate, and can reduce the caking rate of DA-X citrate raw material to below 45%, which indicates820A can better improve the anti-caking property of the citrate original drug.
Formulation # 5 (3%)22LS and 1% Potassium pyrophosphate were compounded) compared to formulation # 7 (2%22LS and 2% potassium pyrophosphate were compounded), showed lower caking rates, and DA-8 and DA-10 both showed similar properties, indicating a preferred mass ratio of silica powder to potassium pyrophosphate of 3:1. Formula 12 (3%)820A and 2% potassium pyrophosphate) showed the lowest caking rate, indicating that the formulation had better put-in anti-caking properties.
TABLE 10 caking Rate of DA-X citrate incorporating the Complex anticaking agent at high humidity
According to the test result of the screening test, 5# to 7# and 11# to 13# and 18# to 20# and the formulas of 24# to 26, 31# to 33# and 37# to 39# are screened as the preferable formulas, namely the formulas of the fatty acid diethylaminoethanol ester citrate of the embodiments 1 to 18.
It should be noted that the foregoing description is only a preferred embodiment of the present invention, and although the present invention has been described in detail with reference to the foregoing embodiments, it should be understood that modifications, equivalents, improvements and modifications to the technical solution described in the foregoing embodiments may occur to those skilled in the art, and all modifications, equivalents, and improvements are intended to be included within the spirit and principle of the present invention.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410113487.8A CN118063336B (en) | 2024-01-26 | 2024-01-26 | Fatty acid diethylamine acyl alcohol ester citrate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410113487.8A CN118063336B (en) | 2024-01-26 | 2024-01-26 | Fatty acid diethylamine acyl alcohol ester citrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118063336A CN118063336A (en) | 2024-05-24 |
| CN118063336B true CN118063336B (en) | 2025-10-31 |
Family
ID=91106715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410113487.8A Active CN118063336B (en) | 2024-01-26 | 2024-01-26 | Fatty acid diethylamine acyl alcohol ester citrate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118063336B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101720762A (en) * | 2008-10-16 | 2010-06-09 | 广州植物龙生物技术有限公司 | Plant growth regulator composite containing diethyl aminoethyl hexanoate and cycogan |
| CN110024811A (en) * | 2019-05-24 | 2019-07-19 | 四川国光农化股份有限公司 | A kind of composition pesticide, preparation and its application |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02229710A (en) * | 1989-02-28 | 1990-09-12 | Sumitomo Chem Co Ltd | Method for preventing caking of ammonium nitrate-based chilling agent freezing mixture |
| AU7348991A (en) * | 1990-02-20 | 1991-09-18 | Jacam Chemical Partners, Limited | Composition and method for absorbing odors |
| CN1171529C (en) * | 1999-07-16 | 2004-10-20 | 福建超大浩伦植物生长剂有限公司 | Plant growth regulator and its preparing process |
| CN114163271A (en) * | 2021-12-06 | 2022-03-11 | 青岛苏贝尔作物营养有限公司 | Humic acid fertilizer additive and preparation method and application thereof |
| CN116023256B (en) * | 2022-12-23 | 2025-03-25 | 日照金禾博源生化有限公司 | Citrate anti-caking method |
| CN116655479A (en) * | 2023-06-05 | 2023-08-29 | 河南省精细化工研究院有限公司 | A kind of synthetic method of novel fertilizer synergist octanoic acid diethylaminoethanol ester citrate |
-
2024
- 2024-01-26 CN CN202410113487.8A patent/CN118063336B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101720762A (en) * | 2008-10-16 | 2010-06-09 | 广州植物龙生物技术有限公司 | Plant growth regulator composite containing diethyl aminoethyl hexanoate and cycogan |
| CN110024811A (en) * | 2019-05-24 | 2019-07-19 | 四川国光农化股份有限公司 | A kind of composition pesticide, preparation and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118063336A (en) | 2024-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101614170B1 (en) | High-fluidity and non-caking pulverulent crystalline maltitol composition | |
| BRPI0713788B1 (en) | COMPOSITION CONTAINING N-ALKYL THIOPHOSPHORUS TRIAMIDE AND USE THEREOF | |
| CN118063336B (en) | Fatty acid diethylamine acyl alcohol ester citrate | |
| Addo et al. | Assessment of anticaking agent on caking behavior of jujube amorphous powder via glass transition and state diagram | |
| CA2385515C (en) | Coating agent and coated particulate fertilizers | |
| US3981732A (en) | Granular p-phenylenediamine color developing agent | |
| US5720794A (en) | Ammonium nitrate particulate fertilizer and method for producing the same | |
| CN116023256B (en) | Citrate anti-caking method | |
| US20130281718A1 (en) | High-fluidity non-caking dianhydrohexitol pellets | |
| CN103783288B (en) | A method for preventing feed grade threonine crystals from agglomerating | |
| CN105055406A (en) | Antibacterial drug aztreonam composition | |
| SE446625B (en) | SET TO MAKE UREAGRANULES AND ARTIFICIAL MIXTURE CONTAINING UREAGRANULES PREPARED BY APPLICATION OF THE PROCEDURE | |
| CN104817523A (en) | A drug ranitidine hydrochloride compound for treating stomach disease and preparation method thereof | |
| CN115606513A (en) | Deodorizing composition for cat litter and preparation method thereof | |
| AU2005258469B2 (en) | Method of estimating caking tendency of sodium hydrogen carbonate crystal grain | |
| JPS61151085A (en) | Hygroscopicity prevention for substance for granular hygroscopic fertilizer | |
| US3512929A (en) | Flowable ammonium thiosulfate and method for its manufacture | |
| CN105001215A (en) | Aztreonam compound serving as sterilization medicine and preparation method thereof | |
| CN117229108B (en) | Liquid preparation containing urease inhibitor and application thereof | |
| CN101302128A (en) | Anticaking agent for nitrocompound | |
| CN121405523A (en) | A Highly Efficient Particulate Ammonium Chloride Anti-caking Agent, Its Preparation and Application | |
| CN105106155A (en) | Fasudil hydrochloride composition tablets capable of improving cerebral vasospasm | |
| CN105055323A (en) | Anti-infective aztreonam composition | |
| CN105055337A (en) | Medicament namely fasudil hydrochloride composite granules for treating cerebral ischemia | |
| CN105012310A (en) | Angiectasis medicine fasudil hydrochloride composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |